The Food and Drug Administration (FDA) has approved Corphedra (ephedrine sulfate injection; Par) for the treatment of clinically important hypotension occurring in the setting of anesthesia. 

Ephedrine sulfate, a sympathomimetic amine, is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent.  Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Ephedrine sulfate stimulates heart rate and cardiac output and variably increases peripheral resistance, resulting in increased blood pressure.  

Related Articles

Corphedra Injection will be available in 50mg/mL,1 mL single-use vials in 25-count cartons. The product is expected to be available in February 2017.

For more information call (800) 828-9393 or visit